The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction

Journal of Perinatal Medicine

Volumn 42, Issue 1, 2014, Pages 61-68

  Schoofs, Katharina ^a   Grittner, Ulrike ^a   Engels, Theresa ^a   Pape, Juliane ^b   Denk, Barbara ^c   Henrich, Wolfgang ^a   Verlohren, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DRK Berlin Westend ^*  (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Angiogenic factors; Biomarker; Hypertension; IUGR; Placental dysfunction; PlGF; Prediction; Preeclampsia; Pregnancy; sFlt 1

Indexed keywords

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; FEMALE; FETUS WEIGHT; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; INFANT; INTRAUTERINE GROWTH RETARDATION; MAJOR CLINICAL STUDY; PREDICTION; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL GROWTH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DECISION SUPPORT TECHNIQUES; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MODELS, STATISTICAL; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTERS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84888188476     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/jpm-2013-0074     Document Type: Article

References (31)

1. Burton GJ, Yung HW, Cindrova-Davies T, Charnock-Jones DS. Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia. Placenta. 2009;30 Suppl A:S43-8.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130-7.
3. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008;21:279-87.
4. Iacovella C, Franchi M, Egbor M, Bhide A, Thilaganathan B. Relationship of first-trimester uterine artery Doppler to late stillbirth. Prenat Diagn. 2012;32:557-61.
5. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol Reprod. 2003;69:1-7.
6. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PFA. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066-74.
7. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005;46:1077-85.
8. Lapaire O, Shennan A, Stepan H. The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application. Eur J Obstet Gynecol Reprod Biol. 2010;151:122-9.
9. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005.
10. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-83.
11. Maynard SE, Crawford SL, Bathgate S, Yan J, Robidoux L, Moore M, et al. Gestational angiogenic biomarker patterns in high risk preeclampsia groups. Am J Obstet Gynecol. 2013 Mar 18. doi:pii: S0002-9378(13)00290-1. 10.1016/j. ajog.2013.03.017. [Epub ahead of print].
12. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-58.
13. Moghbeli N, Srinivas SK, Bastek J, Lu Y, Putt ME, Cappola TP, et al. N-terminal pro-brain natriuretic Peptide as a biomarker for hypertensive disorders of pregnancy. Am J Perinatol. 2010;27:313-9.
14. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007;197:244.e1-8.
15. Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 2010;33:422-7.
16. Pilliod RA, Cheng YW, Snowden JM, Doss AE, Caughey AB. The risk of intrauterine fetal death in the small-for-gestational-age fetus. Am J Obstet Gynecol. 2012;207:318.e1-6.
17. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH. Combined Screening for Preeclampsia and Small for Gestational Age at 11-13 Weeks. Fetal Diagn Ther. 2013;33(1):16-27. doi: 10.1159/000341712. Epub 2012 Sep 13.
18. Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50:137-42.
19. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012;125:911-9.
20. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
21. Schlembach D, Wallner W, Sengenberger R, Stiegler E, Mörtl M, Beckmann MW, et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol. 2007;29:407-13.
22. Shibata E, Rajakumar A, Powers RW, Larkin RW, Gilmour C, Bodnar LM, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab. 2005;90:4895-903.
23. Stepan H, Jank A. Angiogene Faktoren und ihre Rolle in der Entstehung und Vorhersage der Präeklampsie. Z Geburtshilfe Neonatol. 2009;213:101,5.
24. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49:818-24.
25. Thadhani R, Kisner T, Hagmann H, Bossung V, Noack S, Schaarschmidt W, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124:940-50.
26. Vandenberghe G, Mensink I, Twisk JW, Blankenstein MA, Heijboer AC, van Vugt JM. First trimester screening for intrauterine growth restriction and early-onset pre-eclampsia. Prenat Diagn. 2011;31:955-61.
27. Vatten LJ, Eskild A, Nilsen TI, Jeansson S, Jenum PA, Staff AC. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol. 2007;196:239.e1-6.
28. Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2008. p. 592.
29. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161.e1-e11.
30. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58. e1-8.
31. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol. 2001;97:261-7.